Laura A. Carleton

The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance

F. Giles, S. Glynn, J. Lewis, 2013, British Journal of Cancer.